Bellerophon_banner_home_v2_d3

Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
More About Us

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF).

More About Inopulse


Bellerophon Therapeutics, Inc. News Release

A Collection of Bellerophon Therapeutics, Inc. News Release


More News

Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Pipeline



Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF).

More About Inopulse


Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Our Pipeline

Bellerophon Therapeutics, Inc. News Release

A Collection of Bellerophon Therapeutics, Inc. News Release

More News